The U.S. Food and Drug Administration formally rejected objections to its FD&C Red No. 3 delisting decision on August 5, 2026, and lifted the administrative stay that had temporarily suspended the rule’s effective dates.
The action restores the original compliance timeline. The authorization for Red No. 3 in
Red No. 3, also known as erythrosine, is a synthetic red color additive historically used in confectionery, baked goods, decorative frostings, certain beverages, dietary supplements and some orally administered medicines.
FDA issued a final order in January 2025 revoking the color additive’s authorized uses in food and ingested drugs. A subsequent objection and hearing request filed on behalf of Micro-Tracers triggered an administrative stay, temporarily preventing the effective dates from moving forward.
After reviewing the objections, FDA concluded that they did not raise material issues of fact sufficient to justify a formal hearing. The agency therefore rejected the request and lifted the administrative stay effective August 5, 2026.
The August action is not a new initial ban on Red No. 3. Instead, it removes the procedural obstacle that had interrupted implementation of the earlier delisting order.
The practical consequence is that food and pharmaceutical companies again have firm compliance deadlines and can no longer assume that the objection process will delay reformulation indefinitely.
For food manufacturers, the January 2027 deadline leaves a relatively limited period to complete ingredient substitution, stability testing, supplier qualification, label changes and commercial production adjustments.
Replacing Red No. 3 is not always a simple one-for-one color change. Alternative colorants vary in heat stability, light resistance, pH sensitivity, color intensity and compatibility with manufacturing processes.
Natural red colors such as beet-derived pigments, anthocyanins and carmine may behave differently depending on temperature, acidity and storage conditions. Other synthetic colors must be evaluated according to product category and the regulatory requirements of each market.
Manufacturers must therefore balance visual performance with cost, shelf life, consumer expectations and international regulatory differences.
The pharmaceutical industry has a longer transition period, with the deadline for ingested drugs set for January 2028. However, changes to drug formulations can require extensive stability studies, manufacturing validation, supply-chain controls and regulatory submissions.
A longer deadline does not necessarily make the reformulation process less complex.
The decision also has implications beyond the United States. International suppliers exporting candy, baked goods, dietary supplements or oral medicines to the U.S. market must review whether their formulations contain Red No. 3.
Companies serving the United States, European Union, China and other markets may increasingly need flexible formulations and sourcing systems capable of meeting different color-additive rules.
The Red No. 3 phaseout could create new opportunities for suppliers of natural colors, fermentation-derived pigments and formulated color systems designed to provide improved stability.
Demand will not shift evenly to a single replacement. The appropriate alternative will depend on the food category, processing conditions, pH and required shade.
From a regulatory perspective, the FDA action moves the Red No. 3 issue from procedural uncertainty back into implementation.
The central question is no longer whether the deadlines will proceed, but whether manufacturers can complete reformulation and qualification work on time.
Overall, the lifting of the administrative stay restores a clear compliance countdown for food, supplement and pharmaceutical companies.
For global manufacturers still using Red No. 3, the priority has shifted from waiting for a regulatory outcome to executing formulation and supply-chain changes.
